Business Wire

Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO®), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene

Jaa

Vertex Pharmaceuticals (Europe) Limited, today announced that the European Commission has granted Marketing Authorization for SYMKEVI® (tezacaftor/ivacaftor) in a combination regimen with ivacaftor (KALYDECO®) for the treatment of people with cystic fibrosis (CF) aged 12 and older who either have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, or one copy of the F508del mutation and a copy of one of the following 14 mutations in which the CFTR protein shows residual activity: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T. In addition, the European Medicines Agency’s Committee for Orphan Medicinal Products recently recommended the maintenance of orphan designation for tezacaftor/ivacaftor in combination with ivacaftor.

“The authorization of tezacaftor/ivacaftor in combination with ivacaftor is welcome news for European CF patients, their families and everyone involved in their treatment and care. This new medicine is especially important for patients with residual function mutations and those who do not tolerate ORKAMBI® (lumacaftor/ivacaftor),” said Harry Heijerman, Professor and Head of Department of Pulmonology at University Medical Centre Utrecht, The Netherlands.

The EU Marketing Authorization was based on results from two pivotal Phase 3 studies, EVOLVE and EXPAND, published in the New England Journal of Medicine in November 2017. Results showed treatment with tezacaftor/ivacaftor in combination with ivacaftor provides benefits across different CF populations, including statistically significant improvements in lung function, as determined by absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1); with a generally well tolerated safety profile and a lack of increased respiratory adverse events compared to placebo. The improvements in lung function showed a mean absolute change in ppFEV1 compared to placebo of 4.0 percentage points (P<0.0001) and 6.8 percentage points (P<0.0001) in EVOLVE and EXPAND respectively. The most common adverse reactions experienced by patients who received tezacaftor/ivacaftor in combination with ivacaftor in pooled, placebo-controlled Phase 3 studies were headache and nasopharyngitis.

“Today marks an important milestone for many CF patients in Europe, including those who so far have had no available option to treat the CFTR protein defect responsible for their disease,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “With today’s Marketing Authorization, we are rapidly moving towards treating 90 percent of CF patients.”

Tezacaftor/ivacaftor in combination with ivacaftor was approved by the U.S. Food and Drug Administration (FDA) in February 2018 and by Health Canada in June 2018. It is marketed as SYMDEKO™ in the U.S. and Canada.

About CF
Cystic fibrosis is a rare, life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.

CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. There are approximately 2,000 known mutations in the CFTR gene. Some of these mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working or too few CFTR proteins at the cell surface. The defective function or absence of CFTR protein results in poor flow of salt and water into and out of the cell in a number of organs. In the lungs, this leads to the build-up of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the mid-to-late 20s.

About tezacaftor/ivacaftor and ivacaftor
Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface where ivacaftor can increase the amount of time the protein stays open.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu once posted.

About EVOLVE and EXPAND
Data from the two Phase 3 studies EVOLVE and EXPAND were published in the New England Journal of Medicine in November 2017, the studies enrolled approximately 750 people with CF ages 12 and older with two copies of the F508del mutation or with one F508del mutation and a second mutation associated with residual CFTR activity. Across both studies, patients treated with tezacaftor/ivacaftor in combination with ivacaftor experienced statistically significant improvements in lung function, as determined by absolute change from baseline in ppFEV1. The treatment was generally well tolerated; the most common adverse reactions (≥10%) experienced by patients who received tezacaftor/ivacaftor with ivacaftor in the pooled, placebo-controlled Phase 3 studies were headache (14% versus 12% on placebo) and nasopharyngitis (12% versus 10% on placebo).

About orphan designation for medicines
Orphan designation is granted by the European Medicines Agency’s Committee for Orphan Medicinal Products to treatments which either address an existing unmet need or can provide significant benefit for people with life-threatening or chronically debilitating diseases, affecting a small number of patients.

About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for eight years in a row.

Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, as amended, including the quotes in the second and fourth paragraphs of this press release. While the company believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, risks related to commercializing SYMKEVI in Europe and the other risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Contact information

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, +1-617-341-6108
or
Eric Rojas, +1-617-961-7205
or
Zach Barber, +1-617-341-6470
or
Media:
mediainfo@vrtx.com
or
North America:
Heather Nichols, + 1-617-341-6992
or
Europe & Australia:
Marie von Seyfried, + 44 7933 500887

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Andersen Name Premieres in Kuwait27.6.2019 16:30:00 EESTTiedote

Andersen Global announced today one of the premier accounting firms in Kuwait will debut the Andersen name there, furthering the presence of Andersen Global in the Middle East. Causeway Company For Financial Management Consulting W.L.L. in Kuwait will now become Andersen Tax in Kuwait. The firm joined Andersen Global as a collaborating firm last year and will now become a full member firm of the international association. Andersen Tax in Kuwait will continue providing accounting and corporate secretarial services to individuals and corporations in a wide range of industries. “We have a shared dedication toward meeting the needs of our clients, and since becoming a collaborating firm, we gained an appreciation for the way the professionals at the member and collaborating firms of Andersen Global are growing together as an organization. We understand the impact of working with like-minded individuals around the globe with whom we share a commitment to providing seamless service internati

MobileIron Research Reveals 8 in 10 IT Leaders Want to Eliminate Passwords and Expect Mobile Devices to Become Primary Authentication to the Enterprise27.6.2019 15:00:00 EESTTiedote

MobileIron (NASDAQ:MOBL) today revealed the results of a survey conducted with IDG, which found that enterprise users and security professionals alike are frustrated by the inefficiency and lax security of passwords for user authentication. With 90% of security professionals reporting to have seen unauthorized access attempts as a result of stolen credentials, it’s clear that the future of security requires a next generation of authentication that’s more secure. Mobile devices are the best option for replacing passwords, as they remain at the center of enterprises in terms of where business is done, how access is given, and how authentication is done. In fact, the survey revealed that almost nine-in-ten (88%) security leaders believe that mobile devices will soon serve as digital ID to access enterprise services and data. The survey, sponsored by MobileIron, polled 200 IT security leaders in the US, UK, Australia, and New Zealand working in a range of industries at companies with at le

U.S. Food and Drug Administration Supports Principles of Open Sharing of Data27.6.2019 15:00:00 EESTTiedote

The U.S. Food and Drug Administration (FDA), an agency within the Department of Health and Human Services, supports the principle of openly sharing data through efforts like the Patient Safety Movement Foundation’s Open Data Pledge. Creating a healthcare system that embraces data liquidity will help empower patients to actively engage in the development and evaluation of medical devices, enable medical device surveillance to help identify and prevent adverse events from occurring, and enrich the understanding of the benefits and risks of technology utilization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190627005244/en/ FDA Letter of Support for Open Data Sharing By signing the Patient Safety Movement’s Open Data Pledge, leaders in the healthcare technology industry commit to openly sharing non-proprietary data output from their devices and systems without interference or cost. When the data is pulled together into algor

Moody’s and Team8 Launch Joint Venture to Create a Global Cyber Risk Standard27.6.2019 14:00:00 EESTTiedote

Moody’s Corporation (NYSE:MCO) and Team8, a leading cybersecurity think tank and company creation platform, announced today that they have formed a joint venture to establish a global standard for evaluating and assessing cyber risk for enterprises. The joint venture will build on Moody’s experience in developing methodologies and global standards to measure risk, together with Team8’s expertise in cybersecurity technologies, unique access to cyber talent and distinctive understanding of the global cyber threat landscape. This combined expertise will focus on the development of innovative methods and technologies that effectively measure and analyze cyber risks facing global corporations. This will include serving the needs of Boards of Directors, Audit Committees, Chief Executives, Risk and Security Officers for objective cyber risk assessment to better understand companies’ own cyber posture and how it benchmarks against others and over time. The cyber risk service will also assess t

GSMA Announces Winners of 2019 Asia Mobile Awards27.6.2019 14:00:00 EESTTiedote

The GSMA has announced the winners of the 2019 Asia Mobile Awards (AMO Awards), which were presented at the AMO Awards Ceremony and Networking Reception at MWC19 Shanghai. The awards honour the key achievements and innovations driving the mobile industry across the Asia Pacific region. “We congratulate all of the winners and nominees of the Asia Mobile Awards here at MWC19 Shanghai,” said John Hoffman, CEO, GSMA Ltd. “The AMO Awards recognise the most innovative mobile technologies, products and services, while showcasing the positive impact of mobile on individuals, business and society across the Asia Pacific region. We thank all of our entrants, judges and partners for supporting the 2019 Asia Mobile Awards.” The winners of the 2019 Asia Mobile Awards are: Best Mobile Technology Breakthrough in Asia SK Telecom for Innovative Roaming Technology 'baro'. Best IoT Innovation for Mobile Networks in Asia Telstra Corporation Limited, Ericsson for world’s first implementation of a nation-wi

TMD Security Announces Global Agreement to Integrate Easthouse’s Key-less Locks for ATM Top Box and Safe into its TMD Access Management Solution27.6.2019 14:00:00 EESTTiedote

TMD Security announced today that Nanjing Easthouse Electrical Co. Ltd (SecuRam), leading manufacturer of high-security certified locks, will be the hardware partner for TMD’s multi-vendor Access Management solution for ATM top box and safe locks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190627005376/en/ TMD Security has integrated Easthouse’s key-less high-security locks for ATM top box and safe into TMD Access Management, a solution which works for any brand and model of ATM. This is the first single access scheduling and provision solution for ATMs and a wide variety of other access points such as secure room and branch, that uses encrypted one-time-codes and mobile app instead of physical keys. The Access Management solution is currently exclusively available through TMD Security. ‘We are proud to be integrating Easthouse’s ATM top box and safe locks into our ‘game-changing’ Access Management solution,’ said Cees H

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme